Nifty Pharma Jumps Nearly 2% on June 23, 2026: Dr Reddy’s, Sun Pharma and Cipla Lead Gains
- June 23, 2026
- Posted by: Ankit Jaiswal
- Category: News
Nifty Pharma: 25,191 (+1.73%, high 25,294.50). Cipla +2.51% to Rs 1,451. Dr Reddy’s +1.68% Rs 1,312. Sun Pharma +1.50% Rs 1,891. Divi’s Lab +0.76% Rs 6,839. Nifty IT -1.80%.
Nifty Pharma is the best-performing sectoral index on June 23, 2026, rising 1.73% to 25,191 and hitting a session high of 25,294.50, as pharmaceutical stocks attract defensive buying while the Nifty IT index falls 1.80% and the Nifty 50 trades near flat at 24,104. The index’s top contributors today are Cipla (+2.51% to Rs 1,451.20), Dr Reddy’s (+1.68% to Rs 1,312.40), and Sun Pharma (+1.50% to Rs 1,890.80), with Divi’s Laboratories also positive at +0.76% (Rs 6,839). All four pharma names rank among the top Nifty 50 gainers today.
The rally reflects a classic defensive sector rotation: investors moving capital from IT stocks, which are sensitive to US rate cycles and global tech spending, into healthcare names with steady domestic prescription revenue and an active US generics approval pipeline. Kunal Singla, Associate Director at Univest notes that Nifty Pharma’s outperformance by nearly 3.5 percentage points over Nifty IT today is one of the most pronounced intraday sector divergences in recent sessions, driven by the combination of the global AI trade selloff (weighing on IT) and the Fed hawkishness (which benefits defensive healthcare allocation).
Click Here – Get Free Investment Predictions
Nifty Pharma Gainers June 23: Key Stock Data
| Stock | Price (Rs) | Prev Close | Change | % Change |
|---|---|---|---|---|
| Cipla | 1,451.20 | 1,415.70 | +35.50 | +2.51% |
| Dr Reddy’s | 1,312.40 | 1,290.70 | +21.70 | +1.68% |
| Sun Pharma | 1,890.80 | 1,862.90 | +27.90 | +1.50% |
| Divi’s Laboratories | 6,839.00 | 6,787.50 | +51.50 | +0.76% |
| Nifty Pharma Index | 25,191.20 | 24,762.90 | +428.30 | +1.73% |
The divergence between Nifty Pharma (+1.73%) and Nifty IT (-1.80%) is being driven by sector-specific macro sensitivities. IT companies derive 60-80% of their revenue from North American clients, making them highly sensitive to US corporate IT spending cycles, client budget decisions, and the impact of a stronger dollar on revenue realisation. Pharmaceutical companies, by contrast, earn significant revenue from domestic Indian prescription volumes (which grow 8-12% annually irrespective of global macro) and US generic drug approvals (where the USFDA approval pipeline is independent of Fed policy).
Key Drivers of Today’s Rally
Track Nifty Pharma and Pharma Stocks Live on Univest Screener
1. Cipla Leads the Pharma Pack with 2.51% Gain
Cipla’s 2.51% advance to Rs 1,451.20 makes it the top large-cap pharma gainer today. The company has a strong US business driven by complex inhalation generics (Advair equivalent, ProAir equivalent) and oral solid dosage generics from its Goa and Indore facilities. Complex inhalation drugs carry significantly higher margins than commodity generics, supporting Cipla’s earnings quality. The company’s North America revenue has been growing ahead of the segment average, and new product approvals in the inhaler segment could provide further upside to the Cipla story beyond today’s session.
2. Dr Reddy’s and Sun Pharma: The Nifty Pharma Pillars
Dr Reddy’s (+1.68% to Rs 1,312) and Sun Pharma (+1.50% to Rs 1,891) are the two largest components of the index by weighting, and their combined positive performance today is a key driver of the 1.73% advance. Dr Reddy’s has a diversified revenue mix across US generics, Russia/CIS branded generics, and a growing biosimilars pipeline. Sun Pharma benefits from its US specialty dermatology franchise (Ilumya, Levulan) which generates premium margins compared to commodity generic drugs. Both stocks are consensus Nifty Pharma and Nifty 50 outperformers today.
3. Defensive Rotation Narrative: IT Outflows Fund Pharma Inflows
The defensive rotation trade is being accelerated by the Kospi crash today (-5.69%) and the global AI semiconductor trade unwinding. Investors who are reducing exposure to high-PE technology stocks (including Indian IT) are reallocating to sectors with lower equity risk premiums and more visible earnings growth. The pharma sector fits this requirement well: domestic formulation growth is driven by India’s ageing population, rising healthcare awareness, and government health insurance scheme expansion — all independent of global macro cycles.
Conclusion
Nifty Pharma is at 25,191 (+1.73%) on June 23, 2026, led by Cipla (+2.51%), Dr Reddy’s (+1.68%), and Sun Pharma (+1.50%). The index is outperforming the Nifty 50 by 1.73 percentage points and Nifty IT by 3.53 percentage points today, reflecting classic defensive rotation. Track this index and component stocks live on Univest. Consult a SEBI-registered advisor before investing.
Download the Univest iOS App or Univest Android App to track Nifty Pharma and pharma stocks live with research on Univest.
Disclaimer: All data and stock prices are sourced from publicly available information and live exchange feeds as of June 23, 2026. This may not be accurate. Verify with NSE (nseindia.com) and BSE (bseindia.com) before investing. Securities are subject to market risk. Educational content only. Not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Nifty Pharma rising today?
Ans. Nifty Pharma is rising 1.73% to 25,191 on June 23, 2026 primarily due to defensive rotation: investors are reducing exposure to IT stocks (Nifty IT -1.80%) and reallocating to healthcare names with domestic revenue visibility and an active US generics approval pipeline. Cipla (+2.51%), Dr Reddy’s (+1.68%), and Sun Pharma (+1.50%) are the leading contributors.
What is Nifty Pharma today?
Ans. Nifty Pharma is at 25,191.20 on June 23, 2026, up 1.73% (+428.30 points) from the previous close of 24,762.90. The index hit a session high of 25,294.50. It is the best-performing sectoral index today, contrasting sharply with Nifty IT which is down 1.80%.
Which pharma stocks are rising today?
Ans. The top Nifty Pharma gainers today are Cipla (+2.51% to Rs 1,451), Dr Reddy’s (+1.68% to Rs 1,312), Sun Pharma (+1.50% to Rs 1,891), and Divi’s Laboratories (+0.76% to Rs 6,839). All four are among the top Nifty 50 gainers today.
Why is Cipla rising?
Ans. Cipla is rising 2.51% to Rs 1,451.20 on June 23, 2026, as the top Nifty Pharma gainer today. The stock is benefiting from defensive rotation out of IT stocks and its own strong US business in complex inhalation generics, which carry premium margins versus commodity generics.
Why is Nifty IT falling while Nifty Pharma rises?
Ans. Nifty IT is down 1.80% while Nifty Pharma gains 1.73% because the two sectors have opposite macro sensitivities. IT revenue is heavily US-linked and affected by rate cycles, tech spending trends, and dollar strength. Pharmaceutical domestic revenue grows independent of these factors. Defensive investors are selling IT and buying pharma today.
What is Sun Pharma’s performance today?
Ans. Sun Pharma is up 1.50% to Rs 1,890.80 on June 23, 2026. India’s largest pharma company benefits from its US specialty dermatology drugs (Ilumya, Levulan) and branded generics across emerging markets. It is among the top Nifty Pharma contributors today.
Is Nifty Pharma a good investment?
Ans. Nifty Pharma is a defensive sector with earnings driven by domestic prescriptions, US generics approvals, and emerging market branded generics. The sector benefits from India’s growing healthcare spend and USFDA approval pipeline. Investors can access the index through pharma ETFs or individual stock selection. Consult a SEBI-registered advisor for personalised guidance.
What is Divi’s Laboratories?
Ans. Divi’s Laboratories is a contract research and manufacturing services (CRAMS) company that supplies active pharmaceutical ingredients (APIs) to global pharmaceutical multinationals. The stock is up 0.76% to Rs 6,839 as part of today’s Nifty Pharma rally. Divi’s business is driven by long-term supply contracts rather than product launches, providing revenue stability.
